Intervertebral disc degeneration is a major cause of chronic back pain and disability, affecting millions worldwide. Some people develop this condition early in life due to genetic factors—the SM/J mouse strain naturally develops premature disc degeneration, making it useful for studying why this happens. Recent longevity research has shown that senescent cells (cells that have stopped dividing but don't die) accumulate with age and drive many aging-related diseases, including disc degeneration. This study tested whether removing senescent cells could slow disc breakdown in these genetically predisposed mice.
The researchers compared two senolytic drugs (compounds that kill senescent cells): navitoclax alone, and a combination of dasatinib plus quercetin (DQ). In SM/J mice, the DQ combination reduced markers of senescence, lowered inflammatory signals associated with aging cells, and improved the structural integrity and cellular function of the intervertebral disc tissue. Navitoclax alone didn't help. Using genetic sequencing, they identified that DQ treatment affected the JUN signaling pathway—a molecular switch involved in cell aging—and they confirmed this pathway's role by testing the same approach in human degenerative disc cells grown in the lab.
The strengths of this work include testing in two independent mouse strains (SM/J and C57BL/6N), multiple measures of senescence and tissue function, and confirmation of the mechanism in human cells. The transcriptomic analysis (gene expression profiling) provides mechanistic insight beyond just measuring whether the treatment worked. However, this remains preclinical: all experiments were in mice or isolated human cells, with zero human trials completed. We don't know if the dose or dosing schedule used in mice would be safe or effective in people, whether the discs would improve enough to reduce pain, or whether the effect would persist long-term.
The DQ combination is already of interest to aging researchers and has been tested in a small human trial for physical function in older adults, but no large-scale trials exist yet for disc degeneration specifically. This paper provides solid mechanistic evidence that senescent cells contribute to disc degeneration and that clearing them can help—but the translation from mouse to human back pain remains uncertain. The work is technically sound but represents an early-stage preclinical finding that should encourage human studies, not replace conventional treatments.
For the longevity field, this reinforces the senescent cell hypothesis—the idea that removing these cells can improve tissue function and delay age-related disease. The specificity of the JUN pathway and genes like Junb and Zfp36l1 also provides potential biomarkers or drug targets for future work.
0 Comments
Log in to join the discussion.